Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Avanos Medical, Inc.NYSE: AVNS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $5.2M fell 3.7% year over year, ahead of the -6.9% change in trailing-twelve-month research & development. Sequentially, it fell 14.8% from the prior quarter. Over 3 fiscal years it compounded at -8.9% a year.
Context
- Research & development amounted to 3.3% of revenue in FY2025, down 0.5 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -3.7% holds above the trailing-twelve-month pace of -6.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 23.1M USD
- Year-over-year change
- -11.8%
- 4-year CAGR
- -8.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.1M | -11.8% |
| FY2024 | 2024-12-31 | 26.2M | -3.7% |
| FY2023 | 2023-12-31 | 27.2M | -11.1% |
| FY2022 | 2022-12-31 | 30.6M | -5.3% |
| FY2021 | 2021-12-31 | 32.3M | — |
Research & Development vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 research & development of $22.9M is the 6th highest of the 11 companies compared; the peer median is $29.41M.
- Its year-over-year change of -6.9% is the 6th highest of 10, against a peer median of +0.1%.
- Research & development amounts to 3.2% of revenue for AVNS, versus a peer median of 24.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $230.13M | +16.7% | +43.3% | 362.4% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
| LTM Apr 2026 | $89.5M | +0.1% | +5.8% | 10.4% | |
| LTM Mar 2026 | $87.86M | -27.1% | -20.4% | 54.9% | |
| LTM Mar 2026 | $36.35M | -7.6% | +1.5% | 17.8% | |
| LTM Mar 2026 | $22.9M | -6.9% | -8.9% | 3.2% | |
| LTM Mar 2026 | $22.48M | -43.6% | -11.4% | 26.1% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $21.06M | +43.4% | +38.3% | 22.2% |
| LTM Mar 2026 | $15.04M | +14.4% | +8.5% | 37.0% | |
| LTM Mar 2026 | $11.57M | -19.0% | -20.2% | 2.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AVNS) | $29.41M | +0.1% | +5.8% | 24.1% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 744.6M | 684.1M | 673.3M | 687.8M | 701.2M |
| Cost of Revenue | 364.7M | 289.9M | 293.6M | 306.5M | 352.2M |
| Gross Profit | 379.9M | 394.2M | 379.7M | 381.3M | 349M |
| Gross Margin | 51.0% | 57.6% | 56.4% | 55.4% | 49.8% |
| Research & Development | 32.3M | 30.6M | 27.2M | 26.2M | 23.1M |
| Selling, General & Admin | 260.8M | 323.1M | 287.5M | 315.1M | 218.3M |
| Operating Expenses | 293.1M | 352.3M | 314.7M | 341.3M | 410.6M |
| Depreciation & Amortization | 38.3M | 41.1M | 43.5M | 45.5M | 29M |
| EBITDA | 48.9M | 77.8M | 50.6M | (345.6M) | (33.2M) |
| EBITDA Margin | 6.6% | 11.4% | 7.5% | -50.2% | -4.7% |
| Operating Income | 86.8M | 41.9M | 65M | 40M | (61.6M) |
| Operating Margin | 11.7% | 6.1% | 9.7% | 5.8% | -8.8% |
| Interest Income | 200K | 1.2M | 2.9M | 5.1M | 3.2M |
| Interest Expense | 3.3M | 10M | 15M | 12.2M | 4M |
| Other Income / Expenses | (79.5M) | (15.2M) | (72.9M) | (443.3M) | (4.6M) |
| Income Before Tax | 7.3M | 26.7M | (7.9M) | (403.3M) | (66.2M) |
| Pre-Tax Margin | 1.0% | 3.9% | -1.2% | -58.6% | -9.4% |
| Income Tax Expense | 1M | 5.2M | 2M | (17M) | 1.7M |
| Net Income | 6.3M | 50.5M | (61.8M) | (392.1M) | (67.9M) |
| Net Margin | 0.8% | 7.4% | -9.2% | -57.0% | -9.7% |
| EPS (Basic) | 0.13 | 1.08 | (1.33) | (8.53) | (1.46) |
| EPS (Diluted) | 0.13 | 1.07 | (1.33) | (8.53) | (1.46) |
| Weighted Avg Shares | 48.1M | 46.9M | 46.6M | 46M | 46.4M |
| Weighted Avg Shares (Diluted) | 48.6M | 47.3M | 46.6M | 46M | 46.4M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.